ArticleFrontiers in behavioral neuroscience2019
Dopamine D
Article in Frontiers in behavioral neuroscience, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 47 citations in OpenAlex.
- Developing the Dopamine D3 Receptor (D3R) Antagonist, (R)-VK4-116, as a Non-Opioid Medication for the Treatment of Opioid Use Disorder.Medicinal research reviews · 2026Review
- Can the incentive-sensitization theory of addiction incorporate addiction to opioid drugs?Psychopharmacology · 2026Review
- Review
- Large-scale behavioral characterization of oxycodone self-administration in heterogeneous stock rats reveals initial analgesic effects are associated with addiction-like behaviors.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- Negative affective states are not detected in rats following an intravenous self-administration regimen leading to incubation of oxycodone craving.bioRxiv : the preprint server for biology · 2026Article
- Incubation of oxycodone craving is associated with CP-AMPAR upregulation in D1 and A2a receptor-expressing medium spiny neurons in nucleus accumbens core and shell.Neuropharmacology · 2026Article
- High incidence of estrous cycle irregularities in heterogeneous stock (HS) rats is associated with footshock-resistant cocaine intake.Psychopharmacology · 2026Article
- Protocol for a systematic review and meta-analysis of the relationship between opioid exposure and dopaminergic measures in humans assessed by nuclear medicine imaging.Frontiers in psychiatry · 2026Article
- Sex-specific transcriptional signatures of oxycodone persist during withdrawal and abstinence in the suprachiasmatic nucleus of heterogeneous stock rats.Addiction neuroscience · 2025Article
- Perinatal fentanyl exposure drives enduring addiction risk and central amygdala gene dysregulation.Neuropharmacology · 2025Article
- Discovery, Characterization, and Optimization of a Novel Positive Allosteric Modulator-Antagonist of the DJournal of medicinal chemistry · 2025Article
- Escalation of intravenous fentanyl self-administration and assessment of withdrawal behavior in male and female mice.Psychopharmacology · 2025Article
- In vitro safety evaluation of dopamine D3R antagonist, R-VK4-116, as a potential medication for the treatment of opioid use disorder.PloS one · 2024Article
- Effects of selective dopamine D3 receptor partial agonist/antagonists on oxycodone self-administration and antinociception in monkeys.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2023Article
- Oxycodone: A Current Perspective on Its Pharmacology, Abuse, and Pharmacotherapeutic Developments.Pharmacological reviews · 2023Review
- Strain and sex-related behavioral variability of oxycodone dependence in rats.Neuropharmacology · 2023Article
- Chronic administration of a norepinephrine antagonist prevents and partially reverses escalation of cocaine self-administration.Addiction biology · 2023Article
- Pharmacological and Physicochemical Properties Optimization for Dual-Target Dopamine DJournal of medicinal chemistry · 2023Article
- Opioid withdrawal: role in addiction and neural mechanisms.Psychopharmacology · 2023Review
- 3,4-Methylenedioxypyrovalerone High-Responder Phenotype as a Tool to Evaluate Candidate Medications for Stimulant Use Disorder.The Journal of pharmacology and experimental therapeutics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Prescription opioids, such as oxycodone, are highly effective analgesics for clinical pain management, but approximately 25% of patients who are prescribed opioids misuse them, and 5%-10% develop an opioid use disorder (OUD). Effective therapies for the prevention and treatment of opioid abuse and addiction need to be developed. The present study evaluated the effects of the highly selective dopamine D
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.